Aurinia Pharmaceuticals Inc. [NASDAQ: AUPH] stock went on a downward path that fall over -3.60% on Wednesday, amounting to a one-week price decrease of less than -0.27%. The company report on December 9, 2021 that Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN).
– Study demonstrated a favorable risk/benefit profile over a three-year period, with safety comparable to AURORA 1, and sustained efficacy -.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
– Topline results show sustained meaningful reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose oral corticosteroids alone, the active study control -.
Over the last 12 months, AUPH stock rose by 61.45%. The one-year Aurinia Pharmaceuticals Inc. stock forecast points to a potential upside of 29.23. The average equity rating for AUPH stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.87 billion, with 128.44 million shares outstanding and 119.74 million shares in the current float. Compared to the average trading volume of 4.65M shares, AUPH stock reached a trading volume of 2653793 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Aurinia Pharmaceuticals Inc. [AUPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $31.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Aurinia Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on October 28, 2021, representing the official price target for Aurinia Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $30 to $35, while H.C. Wainwright kept a Buy rating on AUPH stock. On November 03, 2020, analysts decreased their price target for AUPH shares from 34 to 28.
The Average True Range (ATR) for Aurinia Pharmaceuticals Inc. is set at 1.86, with the Price to Sales ratio for AUPH stock in the period of the last 12 months amounting to 39.76. The Price to Book ratio for the last quarter was 9.69, with the Price to Cash per share for the same quarter was set at 2.24.
AUPH Stock Performance Analysis:
Aurinia Pharmaceuticals Inc. [AUPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.27. With this latest performance, AUPH shares gained by 22.63% in over the last four-week period, additionally plugging by 73.53% over the last 6 months – not to mention a rise of 61.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 51.53, with the RSI for the last a single of trading hit 54.38, and the three-weeks RSI is set at 50.30 for Aurinia Pharmaceuticals Inc. [AUPH]. The present Moving Average for the last 50 days of trading for this stock 24.50, while it was recorded at 23.09 for the last single week of trading, and 17.16 for the last 200 days.
Insight into Aurinia Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc. [AUPH] shares currently have an operating margin of -194.50. Aurinia Pharmaceuticals Inc.’s Net Margin is presently recorded at -204.88.
Return on Total Capital for AUPH is now -28.27, given the latest momentum, and Return on Invested Capital for the company is -29.81. Return on Equity for this stock declined to -30.14, with Return on Assets sitting at -25.98. When it comes to the capital structure of this company, Aurinia Pharmaceuticals Inc. [AUPH] has a Total Debt to Total Equity ratio set at 2.06. Additionally, AUPH Total Debt to Total Capital is recorded at 2.02, with Total Debt to Total Assets ending up at 1.81. Long-Term Debt to Equity for the company is recorded at 1.87, with the Long-Term Debt to Total Capital now at 1.83.
Reflecting on the efficiency of the workforce at the company, Aurinia Pharmaceuticals Inc. [AUPH] managed to generate an average of -$349,252 per employee. Receivables Turnover for the company is 72.32 with a Total Asset Turnover recorded at a value of 0.13.Aurinia Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.30 and a Current Ratio set at 8.80.
Aurinia Pharmaceuticals Inc. [AUPH] Insider Position Details
There are presently around $1,067 million, or 40.10% of AUPH stock, in the hands of institutional investors. The top three institutional holders of AUPH stocks are: FMR LLC with ownership of 9,336,062, which is approximately 9.54% of the company’s market cap and around 0.20% of the total institutional ownership; MORGAN STANLEY, holding 6,702,366 shares of the stock with an approximate value of $156.37 million in AUPH stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $120.68 million in AUPH stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Aurinia Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 81 institutional holders increased their position in Aurinia Pharmaceuticals Inc. [NASDAQ:AUPH] by around 11,995,181 shares. Additionally, 83 investors decreased positions by around 16,973,489 shares, while 34 investors held positions by with 16,758,395 shares. The mentioned changes placed institutional holdings at 45,727,065 shares, according to the latest SEC report filing. AUPH stock had 39 new institutional investments in for a total of 4,495,218 shares, while 33 institutional investors sold positions of 11,170,476 shares during the same period.